Adial Net Tangible Assets from 2010 to 2026
| ADIL Stock | USD 3.03 0.06 1.94% |
Net Tangible Assets | First Reported 2015-12-31 | Previous Quarter 4.7 M | Current Value 3.3 M | Quarterly Volatility 3.9 M |
Check Adial Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adial Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 215.7 K, Depreciation And Amortization of 617 or Interest Expense of 758.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 109. Adial financial statements analysis is a perfect complement when working with Adial Pharmaceuticals Valuation or Volatility modules.
Adial | Net Tangible Assets | Build AI portfolio with Adial Stock |
Historical Net Tangible Assets data for Adial Pharmaceuticals serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Adial Pharmaceuticals represents a compelling investment opportunity.
Latest Adial Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Adial Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Adial Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adial Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Adial Net Tangible Assets Regression Statistics
| Arithmetic Mean | 1,912,210 | |
| Geometric Mean | 875,488 | |
| Coefficient Of Variation | 112.90 | |
| Mean Deviation | 1,821,833 | |
| Median | 2,732,205 | |
| Standard Deviation | 2,158,869 | |
| Sample Variance | 4.7T | |
| Range | 8.1M | |
| R-Value | 0.61 | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | 259,764 | |
| Total Sum of Squares | 74.6T |
Adial Net Tangible Assets History
About Adial Pharmaceuticals Financial Statements
Adial Pharmaceuticals investors utilize fundamental indicators, such as Net Tangible Assets, to predict how Adial Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 3.2 M | 2.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Adial Pharmaceuticals Correlation against competitors. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.